Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders

ABSTRACT Introduction: Cystic fibrosis (CF) is the most frequent life-shortening autosomal recessive disorder in Caucasians. Defects or absence of the CF-transmembrane conductance regulator impair ion transport in apical membranes of exocrine glands. Leading symptoms of typical CF are exocrine pancreatic insufficiency and progressive pulmonary destruction, causing premature death. Additionally, patients can suffer from chronic rhinosinusitis, hepatic and intestinal involvement, diabetes and predominantly male infertility. Areas covered: CFTR-related disorders affect only one or several different organ systems, often to a milder degree. The definition and usage of the term has seen some variations in the last years, aiming to improve differentiation of the broad clinical spectrum associated with CFTR defects. In this review we present disease characteristics, diagnostic criteria, and treatment options of CFTR-related disorders for a multidisciplinary readership. Expert commentary: CFTR-related disorders are often diagnosed late, leading to lack of specialized attendance and adequate therapy. In clinical care, monitoring of the nutritional status, lung function, airway pathogen colonization and laboratory parameters is necessary to optimize therapy and the course of the disease.

[1]  A. Potter,et al.  Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline* , 2016, Respirology.

[2]  L. Guillot,et al.  Translating the genetics of cystic fibrosis to personalized medicine. , 2016, Translational research : the journal of laboratory and clinical medicine.

[3]  J. Rommens,et al.  Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis , 2015, Nature Communications.

[4]  J. Singer,et al.  Association between Chronic Rhinosinusitis and Health-Related Quality of Life in Adults with Cystic Fibrosis. , 2015, Annals of the American Thoracic Society.

[5]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[6]  W. Fokkens,et al.  Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype? , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  T. McKeever,et al.  Rate of improvement of CF life expectancy exceeds that of general population—Observational death registration study , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  S. Peltz,et al.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Respiratory medicine.

[9]  A. Hinzpeter,et al.  Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. , 2014, The international journal of biochemistry & cell biology.

[10]  W. Cichy,et al.  Liver disease in cystic fibrosis , 2014, Przeglad gastroenterologiczny.

[11]  J. Mainz,et al.  A Patient Nicknamed ‘Saline’: Atypical Course with Cystic Fibrosis , 2013, Klinische Pädiatrie.

[12]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[13]  J. Mainz,et al.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[14]  Peter D Sly,et al.  Risk factors for bronchiectasis in children with cystic fibrosis. , 2013, The New England journal of medicine.

[15]  N. Derichs Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis , 2013, European Respiratory Review.

[16]  David Y. Thomas,et al.  Novel pharmacological strategies to treat cystic fibrosis. , 2013, Trends in pharmacological sciences.

[17]  J. Clancy,et al.  Personalized medicine in cystic fibrosis: dawning of a new era. , 2012, American journal of respiratory and critical care medicine.

[18]  P. Quinton,et al.  β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. , 2012, American journal of respiratory and critical care medicine.

[19]  P. Durie,et al.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  K. Jarvi,et al.  Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? , 2012, Thorax.

[21]  J. Mainz,et al.  Pathogenesis and Management of Nasal Polyposis in Cystic Fibrosis , 2012, Current Allergy and Asthma Reports.

[22]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[23]  B. Kerem,et al.  Recommendations for the classification of diseases as CFTR-related disorders. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[24]  G. Cutting,et al.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. , 2010, The Journal of pediatrics.

[25]  J. Mainz,et al.  Management of chronic rhinosinusitis in CF. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[26]  O. Sommerburg,et al.  European best practice guidelines for cystic fibrosis neonatal screening. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[27]  P. Farrell,et al.  The prevalence of cystic fibrosis in the European Union. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[28]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[29]  A. Moran,et al.  Management of cystic fibrosis‐related diabetes , 2008, Pediatric diabetes.

[30]  S. Paranjape,et al.  Atypical Cystic Fibrosis and CFTR-Related Diseases , 2008, Clinical reviews in allergy & immunology.

[31]  M. Gadjeva,et al.  Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. , 2008, Trends in molecular medicine.

[32]  C. Rudolph,et al.  Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease , 2007, Nature Medicine.

[33]  卢杰,et al.  Cystic fibrosis , 2007 .

[34]  Charles A. Johnson,et al.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. , 2007, The Journal of pediatrics.

[35]  M. Wilschanski,et al.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene , 2007, Gut.

[36]  L. Naehrlich [Sweat testing practices in German cystic fibrosis centres]. , 2007, Klinische Padiatrie.

[37]  Dave P. Miller,et al.  Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function , 2007, Pediatrics.

[38]  M. Stanton,et al.  Cystic fibrosis mortality and survival in the UK: 1947–2003 , 2007, European Respiratory Journal.

[39]  P. Kao,et al.  Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. , 2006, Chest.

[40]  A. Hübler,et al.  Cystic Fibrosis in 65- and 67-Year-Old Siblings , 2006, Respiration.

[41]  F. Ratjen Restoring airway surface liquid in cystic fibrosis. , 2006, The New England journal of medicine.

[42]  G. Chaudry,et al.  Abdominal manifestations of cystic fibrosis in children , 2006, Pediatric Radiology.

[43]  K De Boeck,et al.  Cystic fibrosis: terminology and diagnostic algorithms , 2005, Thorax.

[44]  J. Dankert-Roelse,et al.  Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. , 2005, The Journal of pediatrics.

[45]  F. Accurso,et al.  Complications associated with symptomatic diagnosis in infants with cystic fibrosis. , 2005, The Journal of pediatrics.

[46]  R. Parad,et al.  Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. , 2005, The Journal of pediatrics.

[47]  A. Moran,et al.  Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. , 2005, Diabetes care.

[48]  Massimiliano Mascherini,et al.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients , 2005, European Respiratory Journal.

[49]  K. Gaskin,et al.  The influence of newborn screening for cystic fibrosis on pulmonary outcomes in new South Wales. , 2005, The Journal of pediatrics.

[50]  M. Rosenfeld Overview of published evidence on outcomes with early diagnosis from large US observational studies. , 2005, The Journal of pediatrics.

[51]  M. Kosorok,et al.  Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! , 2005, The Journal of pediatrics.

[52]  N. Høiby,et al.  Eradication of early Pseudomonas aeruginosa infection. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[53]  E. Kerem,et al.  Standards of care for patients with cystic fibrosis: a European consensus. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[54]  M. Rosenfeld,et al.  Update on cystic fibrosis epidemiology , 2004, Current opinion in pulmonary medicine.

[55]  K. Kunzelmann,et al.  Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[56]  J. Baumer Evidence based guidelines for the performance of the sweat test for the investigation of cystic fibrosis in the UK , 2003, Archives of disease in childhood.

[57]  M. Boyle Nonclassic cystic fibrosis and CFTR-related diseases , 2003, Current opinion in pulmonary medicine.

[58]  A. Morabito,et al.  Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome , 2002, Hepatology.

[59]  J. Haddow,et al.  Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians , 2002, Genetics in Medicine.

[60]  M. Kosorok,et al.  Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition , 2001, Pediatric pulmonology.

[61]  J. Emerson,et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.

[62]  B. Strandvik,et al.  Electrogenic ion transport in duodenum, an aid in cystic fibrosis diagnosis. , 2000, Scandinavian journal of gastroenterology.

[63]  C. Férec,et al.  Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis , 2000, The Lancet.

[64]  G. Pier,et al.  Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. Wyllie Gastrointestinal Manifestations of Cystic Fibrosis , 1999, Clinical pediatrics.

[66]  B. Strandvik,et al.  Natural history of liver disease in cystic fibrosis , 1999, Hepatology.

[67]  Charles A. Johnson,et al.  Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada , 1999, Pediatric pulmonology.

[68]  A. Spitzer,et al.  Nutritional Benefits of Neonatal Screening for Cystic Fibrosis , 1998 .

[69]  G. Cutting,et al.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. , 1998, The Journal of pediatrics.

[70]  M. Kosorok,et al.  Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. , 1997, Pediatrics.

[71]  M. Kosorok,et al.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 1997, The New England journal of medicine.

[72]  B. Kerem,et al.  Genotype‐phenotype correlations in cystic fibrosis , 1996, Pediatric pulmonology.

[73]  C. Lamers,et al.  Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. , 1995, Thorax.

[74]  J. Dodge Male fertility in cystic fibrosis , 1995, The Lancet.

[75]  S. Pitzalis,et al.  A specific cystic fibrosis mutation (T3381) associated with the phenotype of isolated hypotonic dehydration. , 1995, The Journal of pediatrics.

[76]  H. Veeze,et al.  Diagnosis of cystic fibrosis. , 1995, The Netherlands journal of medicine.

[77]  M. Knowles,et al.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.

[78]  M. Welsh,et al.  Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[79]  M. Konstan,et al.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. , 1994, American journal of respiratory and critical care medicine.

[80]  B. Kerem,et al.  Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C → T mutation , 1993, The Lancet.

[81]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[82]  M. Corey,et al.  The cystic fibrosis gene and resting energy expenditure. , 1991, The Journal of pediatrics.

[83]  H. D. de Jonge,et al.  Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. , 1991, Gastroenterology.

[84]  H. Levison,et al.  Appendicitis in cystic fibrosis. , 1991, Archives of disease in childhood.

[85]  K. Gaskin,et al.  Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. , 1985, The New England journal of medicine.

[86]  P. Gluckman,et al.  Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[87]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[88]  H. Shwachman,et al.  Water and electrolytes in cervical mucus from patients with cystic fibrosis. , 1973, Fertility and sterility.

[89]  R E COOKE,et al.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. , 1959, Pediatrics.

[90]  H. B. T. Brooks,et al.  Diagnostic Methods , 1916, The Indian Medical Gazette.

[91]  M. Brennan,et al.  Cystic Fibrosis: A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas. , 2016, The Journal of molecular diagnostics : JMD.

[92]  M. Amaral,et al.  New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. , 2015, Pharmacology & therapeutics.

[93]  B. Tümmler,et al.  Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[94]  A Munck,et al.  A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[95]  E. Kerem Atypical CF and CF related diseases. , 2006, Paediatric respiratory reviews.

[96]  M. Claustres Molecular pathology of the CFTR locus in male infertility. , 2005, Reproductive biomedicine online.

[97]  M. Kosorok,et al.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.

[98]  L. Romano,et al.  Uncommon presenting manifestations of cystic fibrosis: A clinical alert , 1995 .

[99]  B. Wilcken Reviews and Notes: Genetics: The Metabolic and Molecular Bases of Inherited Disease , 1995, Annals of Internal Medicine.

[100]  L. Tsui,et al.  Identification of the cystic fibrosis gene: genetic analysis. , 1989, Science.

[101]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.